|
Boner G, Cooper ME, McCarroll K, Brenner BM, De Zeeuw D, Kowey PR, Shahinfar S, Dickson T, Crow RS, Parving HH; RENAAL Investigators. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Diabetologia
48(10):1980-1987, 2005
Rizkalla B, Forbes JM, Cao Z, Boner G, Cooper ME. Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system.
Journal of Hypertension
23(1):153-164, 2005
Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Diabetes
53(11):2921-2930, 2004
Cooper M, Boner G. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
Diabetic Medicine
21(Suppl 1):15-18, 2004
Boner G, Cox AJ, Kelly DJ, Tobar A, Bernheim J, Langham RG, Cooper ME, Gilbert RE. Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?
Nephrology Dialysis Transplantation
18(1):2293-2299, 2003
Boner G, Cao Z, Cooper ME. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
Diabetes Technology and Therapeutics
4(3):313-321, 2002
Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
Diabetologia
44(7):874-877, 2001
Boner G, Cooper ME. Diabetic nephropathy.
Diabetes Technology and Therapeurics
1(4):489-496, 1999
Dr. Geoffrey Boner
Dirección profesional:
81 Kochav Hayam, 40295, Tel Aviv, Israel
|
